Quick Answer
NOVARTIS AG reported Research And Development Expense of $11.20 billion for the year ending 2025.
- NOVARTIS AG showed an increase of +11.8% in Research And Development Expense from 2024 to 2025.
- This data is from NOVARTIS AG's annual report (Form 10-K), filed with the SEC on February 4, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), NOVARTIS AG's Research And Development Expense has grown by 23.9%.
- Historical annual values: Fiscal year 2025: $11.20 billion | Fiscal year 2024: $10.02 billion | Fiscal year 2023: $11.37 billion | Fiscal year 2022: $9.17 billion | Fiscal year 2021: $8.64 billion | Fiscal year 2020: $8.98 billion | Fiscal year 2019: $9.40 billion | Fiscal year 2018: $8.49 billion | Fiscal year 2017: $8.39 billion | Fiscal year 2016: $9.04 billion.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: